Treatment success is reflected in a decreasing serum PSA, but after a variable time period the serum PSA increases although the serum testosterone remains at castrate levels (< 50 ng/dl) and defined as castrate resistant prostate cancer. Here, KLK3 is linked to Familial prostate cancer.